Posted by Michael Wonder on 31 Jul 2018
Soleno Therapeutics receives fast track designation from FDA for DCCR for treatment of Prader-Willi syndrome
30 July 2018 - Phase III clinical trial ongoing at multiple sites in the U.S.
Soleno Therapeutics today announced that the U.S. FDA has granted fast track designation to diazoxide choline controlled-release (DCCR) for the treatment of Prader-Willi Syndrome (PWS). Soleno is currently conducting a Phase III clinical trial of DCCR for the treatment of PWS.
Diazoxide choline has orphan drug designation for the treatment of PWS in the U.S. and E.U.
